A method of treating a hematologic malignant tumor in a subject, comprising administering to a subject a compound having the following structure: or a pharmaceutically acceptable form thereof, wherein the compound is administered in an amount of 15 to 150 mg per day. Use of a compound having the following structure: or a pharmaceutically acceptable form thereof for the manufacture of a medicament for the treatment of a hematologic malignant tumor in a subject where the drug is formulated for administration at a dose of 15 mg to 150 mg of compound per day. The method of claim 1, or the use of claim 2, wherein the compound or a pharmaceutically acceptable form thereof is administered, or formulated for administration, in an amount of 15, 25, 30, 50, 75, 100 or 150 mg per day. The method of claim 1 or the use of claim 2, wherein the compound or a pharmaceutically acceptable form thereof is administered, or they are formulated for administration, once a day or twice a day. The method of claim 1, or the use of claim 2, wherein the compound or its pharmaceutically acceptable form is administered, or formulated for administration, in an amount sufficient to provide a steady concentration of the compound in the plasma at a level greater than IC for PI3K-δ and at a level greater than IC for PI3K-γ.6. The method of claim 1, or the use of claim 2, wherein the compound or a pharmaceutically acceptable form thereof is administered, or formulated for administration, in an amount sufficient to provide a steady concentration of the compound in the plasma of 350 to 450 ng / ml. The method of claim 1 or the use of claim 2, wherein the compound or a pharmaceutically acceptable form thereof is administered, or formulated for administration, at a dose of 25 to 75 mg of BID. The method of claim 1 or the use of claim 2,
